© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Amicus Therapeutics, Inc. (FOLD) shows an Average True Range (ATR) of 0.61 and an Enterprise Value of 3.31B. Its average trading volume over the past 3 months is 7.97M, indicating liquidity. These fundamental metrics provide insight into FOLD's underlying financial health and market activity.
Amicus Therapeutics, Inc. (FOLD) technical indicators as of December 22, 2025: the SMA 20 is 37.52%, SMA 50 at 50.19%, and SMA 200 at 84.87%. The RSI 14 value is 91.12, suggesting its current momentum. These technical analysis signals help assess FOLD's price trends and potential future movements.
Amicus Therapeutics, Inc. (FOLD) stock performance overview as of December 22, 2025: The 52-week high is $14.36 (currently 27.29% below), and the 52-week low is $5.51 (currently 157.35% above). Over the past year, FOLD's performance is 51.5%, compared to the S&P 500's 12.87% change.
According to market data, Amicus Therapeutics, Inc. (FOLD) stock's recent performance metrics show that over the last month, FOLD is 47.86%, with a Year-to-Date (YTD) performance of 50.53%. Over the past year, the stock has seen a 51.5% change. These figures summarize FOLD's price movements across various periods, reflecting its historical returns.
According to current financial data, FOLD stock's P/E (TTM) ratio is 220.08, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for FOLD, including P/S (7.31), P/B (18.98), and P/FCF (451.45), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.